P1327: RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY
Main Authors: | K. Chen, B. Zou, J.-B. Shao, Q. Liu, N. Zhang, P. Fu, X.-H. Sun, H. Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848172.50070.7a |
Similar Items
-
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
by: Alfonso Rodríguez-Gil, et al.
Published: (2022-05-01) -
S231: GLUCOCORTICOID AND GLYCOLYSIS INHIBITORS COOPERATIVELY ABROGATE ACUTE GRAFT-VERSUS-HOST DISEASE
by: Q. wen, et al.
Published: (2022-06-01) -
Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
by: Shuang Fan, et al.
Published: (2022-08-01) -
PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
by: Ó. Muñiz, et al.
Published: (2022-06-01) -
P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
by: L. Van Der Wagen, et al.
Published: (2022-06-01)